pramipexole

Also known as (-)-pramipexole, (S)-N 6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine, (S)-4,5,6,7-tetrahydro-N(6)-propyl-2,6-benzothiazolediamine

Pramipexole, sold under the brand Mirapex among others, is a medication used to treat Parkinson's disease and restless legs syndrome. In Parkinson's disease it may be used alone or together with levodopa. It is taken by mouth. Pramipexole is a dopamine agonist of the non-ergoline class.

Key facts

Drug.Watchedfields: changed
Drug.verifiedrevid: 464213026
Drug.image: Pramipexole.svg
Drug.image_class: skin-invert-image
Drug.image2: Pramipexole 3D-Structure Xtal.png
Drug.image_class2: bg-transparent
Drug.tradename: Mirapex, Mirapexin, Sifrol, others
Drug.MedlinePlus: a697029
Drug.DailyMedID: Pramipexole
Drug.pregnancy_AU: B3
Drug.routes_of_administration: By mouth
Drug.class: Dopamine receptor agonist; Dopamine D2-like receptor agonist; Antiparkinsonian agent

Article

16 sections

Contents

Medical uses
Side effects
Pharmacology
Chemistry
Synthesis
Analogues
Society and culture
Brand names
Research
Further Parkinson's disease symptoms treatment
Cerebral ischemia and reperfusion injury
Traumatic brain injury
Psychiatry
Other indications
Notes
References

Pramipexole was approved for medical use in the United States in 1997 and was first manufactured by Pharmacia and Upjohn. It is available as a generic medication. In 2023, it was the 201st most commonly prescribed medication in the United States, with more than 2million prescriptions.